Please assess the completion status of the following clinical trial:

Trial Title: tDCS to Decrease Opioid Relapse (UG3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* current opioid dependence~* between 21-50 years of age~* recent initiation of buprenorphine or methadone (\<30 days)~Exclusion Criteria:~* current criteria for a DSM-V diagnosis of bipolar disorder, schizophrenia, schizo-affective, schizophreniform, or paranoid disorder~* current suicidality~* evidence of neurocognitive dysfunction~* contraindications for tDCS (e.g seizure disorder)~* probation/parole requirements or an upcoming move that might interfere with protocol participation~* planning to terminate buprenorphine in less than 3 months~* scalp lesions near the tDCS electrode sites

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- tDCS (Type: ACTIVE_COMPARATOR): Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
- sham tDCS (Type: SHAM_COMPARATOR): Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.

Based on this trial design, predict the completion outcome and termination type (if applicable).